HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Leukocyte-Mediated Combined Targeted Chemo and Gene Therapy for Esophageal Cancer.

Abstract
Poor prognosis of esophageal cancer is associated with limited clinical treatment efficacy and lack of targeted therapies. With advances in nanomedicine, nanoparticle drug delivery systems play increasingly important roles in tumor treatment by enabling the simultaneous delivery of multiple therapeutic agents. We here propose a novel nanovector for targeted combination gene therapy and chemotherapy in esophageal cancer. A novel lipid nanovector (EYLN) was designed to carry the chemotherapy drug doxorubicin (Dox) and small interfering RNA against the lipid anabolic metabolism gene LPCAT1, which we previously showed to be significantly overexpressed in esophageal cancer tissues, and its interference inhibited the proliferation, invasion, and metastasis of esophageal cancer cells. This vector, EYLN-Dox/siLPCAT1, was further coated with leukocyte membranes to obtain mEYLNs-Dox/siLPCAT1. The particle size of the coated nanovector was approximately 136 nm, and the surface zeta potential was -21.18 mV. Compared with EYLNs-Dox/siLPCAT1, mEYLNs-Dox/siLPCAT1 were more easily internalized by esophageal cancer cells due to the LFA-1 highly expressed leukocyte membrane coating and showed significant inhibition of the proliferation, migration, and metastasis of esophageal cancer cells, along with their LPCAT1 expression, through more effective delivery of the drugs. Moreover, the nanovectors showed improved blood circulation time, tissue distribution, tumor targeting, and tumor suppression in a mouse model. Thus, combining chemo and gene therapy with this new nanodelivery system achieved greater therapeutic efficacy, providing a new strategy for the treatment of esophageal cancer.
AuthorsYali Jun, Zhuang Tang, Chao Luo, Baofei Jiang, Xiang Li, Mingyue Tao, Hao Gu, Lu Liu, Zhengwei Zhang, Su'An Sun, Kairong Han, Xiaojuan Yu, Xudong Song, Guoquan Tao, Xiaofei Chen, Li Zhang, Yong Gao, Qi-Long Wang
JournalACS applied materials & interfaces (ACS Appl Mater Interfaces) Vol. 12 Issue 42 Pg. 47330-47341 (Oct 21 2020) ISSN: 1944-8252 [Electronic] United States
PMID32997489 (Publication Type: Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Drug Carriers
  • Lipids
  • RNA, Small Interfering
  • Doxorubicin
  • 1-Acylglycerophosphocholine O-Acyltransferase
  • Lpcat1 protein, human
Topics
  • 1-Acylglycerophosphocholine O-Acyltransferase (antagonists & inhibitors, genetics, metabolism)
  • Animals
  • Antibiotics, Antineoplastic (chemistry, pharmacology)
  • Cell Proliferation (drug effects)
  • Doxorubicin (chemistry, pharmacology)
  • Drug Carriers (chemistry)
  • Drug Screening Assays, Antitumor
  • Esophageal Neoplasms (diagnostic imaging, drug therapy, metabolism)
  • Female
  • Genetic Therapy
  • Humans
  • Leukocytes (drug effects, pathology)
  • Lipids (chemistry)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanoparticles (chemistry)
  • Neoplasms, Experimental (diagnostic imaging, drug therapy, metabolism)
  • Particle Size
  • RNA, Small Interfering (chemistry, pharmacology)
  • Surface Properties
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: